Send us Feedback

Elan Corporation (ELN)
Analysis
Data
Financials
(Latest | Earliest) View (previous 50) (next 50)

Show WikiData History

Diff selection: mark the radio boxes of the versions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with current version, (last) = difference with preceding version, M = minor edit.

(cur)(last)21:07, June 29, 2009Wikinvest MaintenanceBot (Talk | contribs) (Hiding Logos)
(cur)(last)15:30, December 14, 200876.204.192.108 (Talk) (→Safety concerns over key drugs compel Elan Corporation to seek EDT sale)[stable]
(cur)(last)16:52, September 17, 2008Vikramparsani (Talk | contribs) (→Elan Corporation's dependence on collaborators like Biogen Idec and Wyeth)[stable]
(cur)(last)16:18, September 17, 2008Vikramparsani (Talk | contribs) (→Elan Corporation's dependence on collaborators like Biogen Idec and Wyeth)
(cur)(last)16:18, September 17, 2008Vikramparsani (Talk | contribs) (→Elan Corporation's dependence on collaborators like Biogen Idec and Wyeth)
(cur)(last)16:17, September 17, 2008Vikramparsani (Talk | contribs) (→Elan Corporation's dependence on collaborators like Biogen Idec and Wyeth)
(cur)(last)16:16, September 17, 2008Vikramparsani (Talk | contribs)
(cur)(last)16:15, September 17, 2008Vikramparsani (Talk | contribs)
(cur)(last)16:15, September 17, 2008Vikramparsani (Talk | contribs) (→Safety concerns over key drugs compel Elan Corporation to seek EDT sale)
(cur)(last)16:14, September 17, 2008Vikramparsani (Talk | contribs)
(cur)(last)16:10, September 17, 2008Vikramparsani (Talk | contribs)
(cur)(last)16:08, September 17, 2008Vikramparsani (Talk | contribs) (→Research and development efforts result in one product entering late-stage clinical trials)
(cur)(last)16:07, September 17, 2008Vikramparsani (Talk | contribs) (→Loss of patent protection for Maxipime and Azactam spurs generic competition)
(cur)(last)16:06, September 17, 2008Vikramparsani (Talk | contribs) (→Loss of patent protection for Maxipime and Azactam spurs generic competition)
(cur)(last)16:04, September 17, 2008Vikramparsani (Talk | contribs) (→Research and development efforts result in one product entering late-stage clinical trials)
(cur)(last)16:01, September 17, 2008Vikramparsani (Talk | contribs) (→Research and development efforts result in one product entering late-stage clinical trials)
(cur)(last)16:01, September 17, 2008Vikramparsani (Talk | contribs) (→Research and development efforts result in one product entering late-stage clinical trials)
(cur)(last)16:00, September 17, 2008Vikramparsani (Talk | contribs) (→Key Trends and Forces)
(cur)(last)15:59, September 17, 2008Vikramparsani (Talk | contribs) (→Loss of patent protection for Maxipime and Azactam spurs generic competition)
(cur)(last)15:58, September 17, 2008Vikramparsani (Talk | contribs)
(cur)(last)15:49, September 17, 2008Vikramparsani (Talk | contribs) (→Major Customers)
(cur)(last)15:48, September 17, 2008Vikramparsani (Talk | contribs) (→Business Segments)
(cur)(last)15:44, September 17, 2008Vikramparsani (Talk | contribs) (→Business Segments)
(cur)(last)15:43, September 17, 2008Vikramparsani (Talk | contribs) (→Business Segments)
(cur)(last)15:42, September 17, 2008Vikramparsani (Talk | contribs) (→Business Segments)
(cur)(last)15:40, September 17, 2008Vikramparsani (Talk | contribs) (→Business Segments)
(cur)(last)15:39, September 17, 2008Vikramparsani (Talk | contribs) (→Research and development efforts result in one product entering late-stage clinical trials)
(cur)(last)15:27, September 17, 2008Vikramparsani (Talk | contribs) (→Business Segments)
(cur)(last)15:17, September 17, 2008Vikramparsani (Talk | contribs) (→Company Overview)
(cur)(last)15:17, September 17, 2008Vikramparsani (Talk | contribs)
(cur)(last)15:16, September 17, 2008Vikramparsani (Talk | contribs) (→Company Overview)
(cur)(last)15:13, September 17, 2008Vikramparsani (Talk | contribs) (→Company Overview)
(cur)(last)15:09, September 17, 2008Vikramparsani (Talk | contribs) (→Company Overview)
(cur)(last)15:03, September 17, 2008Vikramparsani (Talk | contribs)
(cur)(last)15:01, September 17, 2008Vikramparsani (Talk | contribs)
(cur)(last)15:00, September 17, 2008Vikramparsani (Talk | contribs)
(cur)(last)14:38, September 17, 2008Vikramparsani (Talk | contribs)
(cur)(last)14:32, September 17, 2008Vikramparsani (Talk | contribs)
(cur)(last)14:31, September 17, 2008Vikramparsani (Talk | contribs)
(cur)(last)14:30, September 17, 2008Vikramparsani (Talk | contribs)
(cur)(last)19:48, September 16, 2008Vikramparsani (Talk | contribs)
(cur)(last)19:48, September 16, 2008Vikramparsani (Talk | contribs)
(cur)(last)00:08, September 15, 2008Vikramparsani (Talk | contribs)m (Reverted edits by Vikramparsani (Talk); changed back to last version by Parkerconrad)
(cur)(last)00:07, September 15, 2008Vikramparsani (Talk | contribs)
(cur)(last)18:48, September 11, 2008Vikramparsani (Talk | contribs) (→Rare and lethal side effect continues to adversely affect the reputation of Tysabri)
(cur)(last)18:45, September 11, 2008Vikramparsani (Talk | contribs) (→Rare and lethal side effect continues to adversely affect the reputation of Tysabri)
(cur)(last)18:44, September 11, 2008Vikramparsani (Talk | contribs) (→Rare and lethal side effect continues to adversely affect the reputation of Tysabri)
(cur)(last)18:42, September 11, 2008Vikramparsani (Talk | contribs) (→Rare and lethal side effect continues to adversely affect the reputation of Tysabri)
(cur)(last)10:15, September 3, 2008Parkerconrad (Talk | contribs)
(cur)(last)16:54, September 2, 2008Adamfarren (Talk | contribs)
(Latest | Earliest) View (previous 50) (next 50)
Retrieved from "http://www.wikinvest.com/stock/Elan_Corporation_(ELN)"
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki